Good publication guidance for pharma companies to be updated
This article was originally published in Scrip
The guidance, Good Publication Practice for Pharmaceutical Companies, is being updated by a steering committee of the International Society for Medical Publication Professionals (ISMPP), and it is inviting participation in the process from those with experience in developing publication policies, scientific writing and designing clinical trials. The guidance is nearly a decade old.
You may also be interested in...
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
AveXis/Novartis’s one-time AAV9 vector-based intravenous gene therapy for spinal muscular atrophy, Zolgensma, continues to have beneficial effects up to five years after its administration to babies, and an intrathecal formulation has significant promise in older infants.
Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis.